Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Tricuspid Valve Infective Endocarditis Treated with Autologous Pericardium:Report of a Case].

Created on 11 Sep 2026

Authors

Ryuji Hojo, Yosuke Motoharu, Eiichi Teshima, Kai Machida, Ryuji Tominaga, Tsuyoshi Ito

Published in

Kyobu geka. The Japanese journal of thoracic surgery. Volume 79. Issue 4. Pages 291-294.

Abstract

Right-sided infective endocarditis( IE) is rare, accounting for 5~10% of all cases. Herein, we report a 70-year-old man who developed methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and tricuspid valve endocarditis (TVE) with severe tricuspid regurgitation (TR) following bladder fistula placement. Echocardiography revealed a 17×14 mm vegetation on the septal leaflet. Despite antibiotic therapy, the symptoms of heart failure worsened and surgery was indicated. Under cardiopulmonary bypass, the infected anterior and septal leaflets were excised, and valve reconstruction was performed using glutaraldehyde-treated autologous pericardium. Postoperative echocardiography revealed mild TR. The patient underwent prolonged antibiotic therapy and was discharged in good condition. At two years follow-up, there was no recurrence of infection or worsening of TR. This case suggests that autologous pericardial patch repair is a useful strategy for MRSA-associated TVE, particularly in patients with a high reinfection risk, where prosthetic material should be avoided.

PMID:
42722504
Bibliographic data and abstract were imported from PubMed on 11 Sep 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement